AG Prof. Dr. med. Anne Flörcken
Sie befinden sich hier:
Focus of research
Our group focuses on translational research projects in oncology, especially in soft tissue and bone sarcoma diseases. Our main topic is the clinical, immunological, and molecular characterization of the Charité cohort of soft tissue and bone sarcomas to identify reliable predictive and prognostic markers and to ultimately improve therapeutic options.
A second focus is the understanding of immunomodulatory processes in malignant diseases, mainly in metastatic renal cell carcinoma. Our group concentrates on the understanding of novel targeted therapies and immunotherapeutics such as tyrosine kinase inhibitors and checkpoint inhibitors. We study their mechanisms of action, toxicities, and modulation of biomarkers.
We contribute to national clinical study groups and are part of multiple local and national cooperations.
Oberärztin der Klinik, W2-Professur für Klinisch Translationale Sarkom-Forschung
Selected publications
- Striefler JK , Schmiester M , Brandes F , Dörr A, Pahl S , Kaul D , Rau D , Dobrindt EM , Koulaxouzidis G , Bullinger L , Märdian S , Flörcken A. Comorbidities rather than older age define outcome in adult patients with tumors of the Ewing sarcoma family. Cancer Med 2022;11(17):3213-3225. PubMed
- Markó L, Dörr A, Linz P, van den Meiracker AH, Garrelds IM, Kuehne T, Dechend R, Danser AHJ 7, Flörcken A , Müller DN (shared last). Effect of Sunitinib Treatment on Skin Sodium Accumulation in Patients With Renal Cancer: a Pilot Study. Hypertension 2022 May;79(5):e103-e105. PubMed
- Brandes F, Striefler JK, Dörr A, Schmiester M, Märdian S, Koulaxouzidis G, Kaul D, Behzadi A, Thuss-Patience P, Ahn J, Pelzer U, Bullinger L, Flörcken A. Impact of a specialised palliative care intervention in patients with advanced soft tissue sarcoma – a single-center retrospective analysis. BMC Palliat Care. 2021 Jan 14;20(1):16 PubMed
- Schmiester M, Dolnik A, Kornak U, Hummel M, Pfitzner B, Treue D, Hartmann A, Agaimy A, Weyerer V, Lekaj A, Brakemeier S, Peters R, Öllinger R, Märdian S, Bullinger L, Striefler JK, Flörcken A. TFE3 Activation in a TSC1-Altered PEComa: Challenging the Dichotomy of the Underlying Pathogenic Mechanisms. J Pathol Clin Res. 2021 Jan;7(1):3-9. PubMed
- Striefler JK, Brandes F, Baur A, Pfitzner BM, Kaul D, Rau D, Dörr A, Schmiester M, Koulaxouzidis G, Bullinger L, Märdian S, Flörcken A. Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience. BMC Cancer 2020, 20(1):68. PubMed
- Flörcken A, Grau M, Wolf A, Weilemann A, Kopp J, Dörken B, Blankenstein T, Pezzutto A, Lenz P, Lenz G, Westermann J. Gene expression profiling of peripheral blood mononuclear cells during treatment with a gene-modified allogeneic tumor cell vaccine in advanced renal cell cancer: Tumor-induced immunosuppression and a possible role for NF-kB. International Journal of Cancer 2015, 136(8):1814-26. PubMed
- Flörcken A, Kopp J, van Lessen A, Movassaghi K, Takvorian A, Jöhrens K, Möbs M, Schönemann C, Sawitzki B, Egerer K, Dörken B, Pezzutto A, Westermann J. Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: a clinical phase I/II study. Human Vaccines & Immunotherapeutics 2013, 9(6): 1217-27. PubMed
- Johannsen M, Flörcken A (shared first authorship), Bex A, Roigas J, Cosentino M, Ficarra V, Kloeters C, Rief M, Rogalla P, Miller K, Grünwald V. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. European Urology 2009, 55(6):1430-8. PubMed